Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Assets (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Current Assets for 13 consecutive years, with $418.5 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 159.8% to $418.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $418.5 million through Dec 2025, up 159.8% year-over-year, with the annual reading at $418.5 million for FY2025, 159.8% up from the prior year.
  • Current Assets for Q4 2025 was $418.5 million at Theravance Biopharma, up from $354.7 million in the prior quarter.
  • The five-year high for Current Assets was $511.7 million in Q3 2022, with the low at $116.5 million in Q3 2024.
  • Average Current Assets over 5 years is $247.9 million, with a median of $227.3 million recorded in 2021.
  • The sharpest move saw Current Assets crashed 68.4% in 2023, then surged 207.02% in 2025.
  • Over 5 years, Current Assets stood at $249.9 million in 2021, then soared by 41.46% to $353.5 million in 2022, then tumbled by 62.22% to $133.5 million in 2023, then increased by 20.61% to $161.1 million in 2024, then surged by 159.8% to $418.5 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $418.5 million, $354.7 million, and $366.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.